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1. Introduction
  Malaria is a parasitic disease, leading to severe harm 
to human health and social development. Generally, the 
safe, cheap and effective vaccine is considered as the key 
in controlling and eliminating malaria. So WHO, United 
Nations Development Programme, World Bank etc. have 
listed the development of vaccine against malaria as one of 
prior vaccine projects[1]. Mueler et al found that sporozoites 
of Plasmodium with UIS3 gene knockout displayed 
detoxification action. After infecting animal models, these 
sporozoites stayed in hepatocells not in red blood cells. 
They can be used as detoxification vaccine, and have 
immuno-protective effect on mice with malaria[2]. Based 
on Mueler’s research, this study transferred exogenous 
immunoenhancing gene into detoxified sporozoites of 
Plasmodium berghei. It could strengthen immune ability of 
these sporozoites and may become more effective vaccine 
model. As a speific chemokine of B cells , B-lymphocyte 
chemoattractant (BLC) can stimulate B-lymphocyte 
receptor-1 expression, guide the migration and homing of 
B cells, promote immune response by attracting B cells 
and CD4+ T cells[3,4]. In our study, cDNA of BLC gene was 
amplified, and inserted into plasmid of Plasmodium berghei 
gene with knockout. It is proved BLC can be expressed in 
eukaryocyte, and this could pave the way for development 
of immunoenhancing detoxified vaccine.
2. Materials and methods
2.1. Materials and reagents
  Spleen tissues were from three-week BALB/c mice in 
Hainan Provincial Key Laboratory of Tropical Medicine. 
Plasmid of Plasmodium berghei gene with UIS3 knockout 
pAKM19 was provided by Matuschewsk. COS-1 cells 
were from Hainan Provincial Key Laboratory of Tropical 
Medicine. Lipofectamine was from Gibcol BRL. PT-PCR kit 
(TaKaRa RNA PCR Kit ver 2.1), restrictive endonuclease 
Hind Ⅲ, EcoRⅠ,  Bam Ⅰ, T4 DNA ligase, standard nucleic 
acid marker and standard protein marker were purchased 
from TaKaRa Company. Trizol Reagent was from Invitrogen 
Co. Plasmid extraction kit (QIQGEN plasmid mini kit), gel 
recycle kit (QIAquick gel extraction kit) and anti-mice 
BLC antibody were from Sigma Co. Horseradish peroxidase 
labeling anti-rat IgG antibody was from Dako Company, 
DAB from Zhongshan Biological Technological Company in 
Beijing, and Tris-Cl, SDS, glycine from Bio RAD Co.
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2.2.1. Primer design and synthesis
  According to BLC sequence of mice from genetic library 
(NM-018866.2), the primer was designed by Oligo 6.01 as 
following:
F 5’-ACAGCTAGCATGAGGCTCAGCACAGCA AC-3’
R5’-CGACTCGAGTCAGGCAGCTCTTCTCTTAC-3.
NheⅠsite (GCTAGC) and three protective bases were 
inserted into 5’ end of forward primer, while Xho Ⅰsite 
(CTCGAC) and three bases were added into 5’ end of reverse 
primer. The length of PCR product was 372 bp.
2.2.2. Total RNA extraction and RT-PCR
  A total of 500 mg spleen tissue from mice were grinded 
and added with TRIzol Reagent based on the instruction. 
With the reverse primer as reactant, reverse transcription 
reaction was conducted under following condition: 30 ℃ 10 
min,50 ℃ 30 min,99 ℃ 5 min,5 ℃ 5 min. Then PCR was 
performed as following: 94 ℃ 30 sec,60 ℃ 90 sec.72 ℃ 150 
sec, 30 cycles, 72 ℃ 10 min.
2.2.3.Construction of BLC transgenic plasmid
  Based on the instruction, amplified cDNA of BLC and 
pAKM19 with UIS3 knockout were treated by double enzyme 
digestion of  Nhe Ⅰand Xho. Responding fragments were 
recycled by 1% agarose electrophoresis. Under the ligation 
of T4 DNA, vector and target gene fragment were put together 
overnight at 16 ℃. Competent cells were transformed into 
Escherichia coli JM109, and monoclones were screened for 
amplification and culture. Then plasmid was extracted 
based on QIQGEN plasmid mini kit protocol for further 
identification.
 
2.2.4. Identification and sequencing
  After amplification and extraction, positive clones were 
digested by restrictive endonuclease such as Nhe Ⅰand 
Xho, or other enzymes like BamⅠ. These clones with 
correct fragment were selected for DNA sequencing (Jikang 
Biological Technological Company in Shanghai). 
2.2.5. Transfection into COS-1 cells
  According to instruction from Jiao et al[5] and manual for 
lipofectamine transfection from Gibcol BRL Co., recombinant 
plasmid was transfected into COS-1 cells. COS-1 cells were 
resuspended in complete medium, inoculated into 6-well 
plate at 1.5伊106-2伊106 cells/well, then cultured at 37 ℃ 
for 18-24 h until 60%-80% fusion. Liposome was used as 
mediator. Two solutions were prepared in sterile tubes: A 
solution including 2 毺g DNA and 100 毺L culture solution 
free of serum, and B solution including 6 毺L lipofectamine 
and 50 毺L culture solution free of serum. Then two 
solutions were mixed, and incubated at room temperature for 
30 min to obtain DNA-liposome complex. Cells were washes 
twice with Dulbecco’s modified Eagle’s medium (DMEM) 
free of serum. Then 0.8 mL free-serum DMEM was mixed 
with complex, and the mixture was dropped into COS-1 cells. 
These cells were incubated under 5% CO2 , 37 ℃ for 8-14 h. 
Two mL complete medium were added. After incubation for 
48 h, cells or supernatants were harvested.
2.2.6. BLC expression assay by Western blotting and RT-
PCR
  Cell lysis solution or supernatant was mixed with 2伊SDS, 
boiled at 100 ℃ for 5 min. After SDS/PAGE electrophoresis, 
isolated proteins were transferred on the PVDF membrane, 
and analyzed by Western blotting with anti-mice BLC 
antibody as the first antibody and anti-rat IgG antibody as 
the secondary[6]. While BLC mRNA expression was tested by 
RT-PCR as 1.2.2.
3. Results 
3.1. RT-PCR result
  The expected length of amplified product of BLC gene 
by PCR was 372 bp. And 1% agarose gel electrophoresis 
analysis showed the consistent length from 300 bp to 400 bp 
(Figure 1A).
3.2. Construction, identification and sequencing of 
recombinant plasmid
  After enzyme digestion with NheⅠ and XhoⅠ, BLC 
fragment in 327 bp length and pAKM19 liner fragment in 3 400 
bp were obtainable in prediction. And there could be two 
fragments in 1 000 bp and 3 000 bp length, respectively under 
BamⅠdigestion. The analysis exhibited the same result 
(Figure 1B). While the blast comparison showed amplified 
cDNA of BLC and the open reading frame of pAKM19 were 
correct (Figure 2). It proved the successful construction of the 
recombinant plasmid, named as pUIS3-BLC+ .
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Figure 1. Amplification of BLC by RT-PCR and identification of 
plasmid pUIS3-BLC+ by enzymatic digestion.
3.3. Identification of BLC mRNA expression in tansfected 
eukaryocyte by pUIS3-BLC+ 
  RT-PCR revealed that BLC mRNA expression in transfected 
COS-1 cells by pUIS3-BLC+ were half of 毬-actin expression, 
while no expression was available in un-transfected COS-1 
cells (Figure 3A). It indicated recombinant plasmid pUIS3-
BLC+ had BLC gene expression in eukaryocyte.
3.4. Identification of BLC protein expression in tansfected 
eukaryocyte by pUIS3-BLC+
  Western blotting analysis showed a new protein zone with 
molecular weight about 9.8 kD only in transfected COS-1 
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cells (Figure 3B), indicating pUIS3-BLC+ also had BLC protein 
expression in eukaryocyte.
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Figure 3. BLO expression in COS-1.
A: RT-PCR, B:Western blotting.
4. Discussion
  Chemokines refer to a series of secretory single-chain 
proteins, which have molecular weight 8-12 kD, at least 
two CYS conservative sequences and chemotaxis effect on 
leucocyte[7]. According to amount and location of CYS in 
primary structure of chemokine, they are classified into four 
types: CXC chemokine (毩, CXCL, SCYA) , CC chemokine (
毬, CCL, SCYB), C chemokine (毭, XCL, SCYC) and CX3C 
chemokine (δ, CX3CL, SCYD). BLCs belong to CXC type, 
and come from lymphatic organs including spleen, thymus, 
lymph node, appendix etc.[8,9]. It is reported BLCs play 
important role in formation of germinal center and induction 
of organism into specific immune response[8]. The expression 
of chemokine in tumor tissue can promote immune response 
in tumor by autocrine or paracrine, and provide strong 
and lasting anti-tumor immunity to organism. Nowadays, 
malaria is a severe disease due to tropical parasites. It leads 
to over 10 million deaths every year, and brings serious 
harm into human health[10]. Development of new-style and 
effective vaccine is the main strategy for eradicating or 
controlling malaria. However, researches on vaccine against 
malaria for more than 100 years suggest strengthening 
intensity and prolonging time of immune response are 
bottleneck problems in the development. At present, it 
has been reported that it is possible to delay the growth of 
Plasmodium by inactivating expressive gene during some 
period with gene engineering technology. Muelar et al found 
that sporozoites of Plasmodium with UIS3 gene knockout 
displayed detoxification action. After infecting animal 
models, these sporozoites stayed in hepatocells not in red 
blood cells. They can be used as detoxification vaccine, 
and have immuno-protective effect on mice with malaria[2]. 
According to Mueler’s study, immunoenhancing BLC gene 
was transferred into sporozoites of Plasmodium berghei with 
UIS3 gene knockout to constructed recombinant plasmid 
encoding BLC gene in our study. 
  BLC gene was amplified and cloned by RT-PCR, then 
inserted into 3’ end of recombinant plasmid of Plasmodium 
berghei with UIS3 gene knockout. The homologous sequence 
in the recombinant plasmid guarantees the transgenosis 
of BLC. After restrictive endonuclease digestion and DNA 
sequencing, blast comparison proves the correct open 
reading frame. RT-PCR and Western blotting assay show gene 
and protein of BLC can be expressed in transfect COS-1 cell, 
indicating after transferring into Plasmodium recombinant 
plasmid expression is available in infected animal host. 
This study paves the way for further development of new-
style malaria vaccine with detoxification because of UIS3 
knockout, and immunoenchancement because of BLC.   
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Figure 2. Identification of plasmid pUIS3-BLC+ by sequencing and blasting.
